AlphAIalphai — Financial news for AI agents
tradingview.comAUG 121 min read$ERAS

Erasca, Inc. Stock 12‑Month Price Target Raised to $22.73, Implies 24% Upside

Analyst estimates for Erasca, Inc. show the average 12-month price target increased from $22.55 to $22.73, with a range of $18 to $30, according to 11 analysts. Based on the Aug. 11 close, the target suggests about 24% upside. The consensus rating remains “Buy” with 9 Buys, 2 Holds, and 0 Sells.

Original reporting
tradingview.com
Published Aug 12, 2026, 2:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.73, Implies 24% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$ERASBullishLow
01

Why it matters

For traders, the actionable signal is limited to sentiment and expectations, not a new operational or financial datapoint.

02

Market read

Consensus target uptick suggests slightly improved Street outlook, but without new fundamentals the trading edge is small.

03

What to watch

The article does not break out which analysts raised targets, the magnitude of estimate changes, or any new drivers behind the revision.

Relevance 4/10Novelty 4/10Timing: published mid-afternoon, same day as the target update

Background

The piece summarizes FactSet-sourced consensus analyst price target changes and rating distribution for Erasca.

Company-level read

Ticker impact

$ERASBullishMedium confidence
Context

Erasca’s average 12-month analyst price target rose from $22.55 to $22.73, with a 24% implied upside versus the Aug. 11 close.

Expected impact

Near-term bias modestly positive, but likely limited follow-through because the update is incremental and not tied to new company-specific results.

Evidence & confidence

Only the consensus price target and implied upside are updated; there is no mention of earnings, guidance, trial data, contracts, or other primary catalysts.

Market effects

Sector

Minimal, since this is a single-name analyst target adjustment without sector-wide new information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A higher consensus target can reflect model recalibration rather than improved fundamentals, so price may not follow if the underlying thesis is unchanged.

Key entities

  • company
    Erasca, Inc.

    Subject of the article, with consensus 12-month price target raised to $22.73 and Buy rating maintained.

Read at source← All news

Related articles

AUG 23
$ERASHighAI 8/10

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.

stocktwits.com2 min
AUG 19
$ERASMedAI 8/10

Erasca (ERAS) Loss Widens As New R And D Chief Tests Whether The Stock Is Pricey

Erasca (ERAS) reported a wider net loss of $287.223M in Q2 2026 and appointed Charles S. Fuchs as R&D president. The stock trades at $18.10, with 90-day and YTD returns of 55.97% and 404.18%, respectively. Despite a high P/B ratio of 17.5x, the company has no revenue and forecasts losses for the next three years. The article questions whether the stock is overvalued.

simplywall.st3 min
AUG 11
$ERASMedAI 8/10

Erasca, Inc. (ERAS): Results of Operations and Financial Condition

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Erasca Reports Second Quarter 2026 Business Updates and Financial Results Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as

SEC EDGAR 8-K6 min
JUL 15
$ERASMedAI 8/10

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Erasca, Inc. (Nasdaq: ERAS) said it closed an upsized public offering of 36,142,857 shares of common stock at $17.50 per share, including 4,714,285 shares from the underwriters’ option. Gross proceeds were about $632.5 million. Erasca plans to use net proceeds for R&D, working capital, and general corporate purposes.

manilatimes.net2 min
JUL 15
$ERASMedAI 8/10

Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

Erasca Inc. (NASDAQ:ERAS) shares rose 8.94% to $19.50 after phase 1 data for ERAS-0015 in RAS-mutant solid tumors. In pancreatic cancer, tumors shrank 57% after eight weeks in 7 patients. Jefferies raised its price target 14% to $24 and reiterated a buy. Erasca launched a follow-on offering to raise up to about $632M.

insidermonkey.com6 min